Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine + azithromycin vs lopinavir/ritonavir + hydroxychloroquine in hospitalized COVID-19
2020-001605-23Phase 4Terminated
- Sponsor
- Osakidetza
- Start
- May 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in coronavirus disease 2019 (COVID-19) comparing hydroxychloroquine + azithromycin with lopinavir/ritonavir + hydroxychloroquine (2 arms). Primary endpoints: Respiratory severity scale Brescia-COVID and Time to improvement on Brescia-COVID respiratory severity scale. Started May 2020; status: terminated.
02
Drugs
hydroxychloroquineazithromycinlopinavirritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001605-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001605-23.